CSPC Pharmaceutical Group Limited
1093.HK1093.HK · Stock Price
Historical price data
Overview
CSPC Pharmaceutical Group's mission is to deliver high-quality, accessible pharmaceutical products while advancing innovative therapeutics through sustained R&D investment. The company has achieved a dominant position in China's nervous system and cardiovascular markets, established itself as a global API supplier, and is now transitioning toward a more innovation-driven future with several novel drug candidates in late-stage development. Its strategy hinges on leveraging its integrated manufacturing and distribution strengths to maximize the lifecycle of its established products while systematically commercializing its innovative pipeline to capture higher-margin opportunities.
Technology Platform
Integrated platform spanning small molecule discovery, biologics/antibody-drug conjugate (ADC) development, advanced drug delivery systems, and scalable process manufacturing.
Pipeline
7| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Butylphthalide + Butylphthalide placebo | ST-segment Elevation Myocardial Infarction (STEMI) | Phase 3 | |
| Venetoclax Combining Chidamide and Azacitidine (VCA) regimen... | Leukemia, Myeloid, Acute | Phase 2 | |
| pegylated liposomal doxorubicin (PLD) + PD-1 | Muscle Invasive Bladder Cancer | Phase 2 | |
| Sintilimab + Nab paclitaxel + Cisplatin | Esophageal Squamous Cell Carcinoma | Phase 2 | |
| Mitoxantrone hydrochloride liposome Injection-based bridging... | B-cell Acute Lymphoblastic Leukemia | Phase 2 |